Lucknow, Aug 2026 : Amid an ongoing crackdown on counterfeit and substandard medicines, the Food Safety and Drug Administration Department has recommended expanding the scope of an investigation into a case registered at Aminabad police station. Drug Inspector Vivek Kumar Singh has requested that Bal Govind, proprietor of Shri Raj Rajeshwar Enterprises, and Rohit Chadha, proprietor of Shri Banke Bihari Pharma, be brought into the investigation and that further action be taken against them.
Suspicious Transactions Found in Marg Software
During inspections of both firms on August 3, officials examined their Marg Software records and stock ledgers. The investigation reportedly found records showing that Shri Raj Rajeshwar Enterprises purchased large quantities of Kenacort 40 mg vials from Bharat Pharma in Aminabad and subsequently sold them to Banke Bihari Pharma.
According to the records, 1,440 vials were purchased from Bharat Pharma on April 25, 2025, and shown as sold to Banke Bihari Pharma on May 6, 2025. Similarly, 720 vials were purchased and sold on June 22, 2025. The records also indicate that the latter consignment of 720 vials was subsequently returned through a debit note.
No Physical Bill for 3,600 Vials
One of the most significant findings relates to a transaction involving 3,600 Kenacort 40 mg vials. Banke Bihari Pharma's Marg Software showed the purchase of these vials from Shri Raj Rajeshwar Enterprises, but no physical invoice was produced for the transaction.
According to the department, proprietor Rohit Chadha stated that an invoice for 720 vials had been provided, while the bill for the remaining 3,600 vials was supposed to be supplied later. Despite being given time to produce the relevant records, the firm reportedly failed to provide a response or clarification.
At the same time, Bal Govind, proprietor of Shri Raj Rajeshwar Enterprises, reportedly denied having sold 3,600 vials to Banke Bihari Pharma.
720 Vials Missing From Physical Stock
The investigation also found discrepancies in the stock records of Banke Bihari Pharma. The firm's ledger for the financial year 2025-26 showed a closing stock of 720 vials, while the opening balance for 2026-27 was recorded as zero.
Officials also reportedly failed to find the corresponding 720 vials during physical inspection. As a result, authorities could not collect samples of the medicine for laboratory testing and analysis.
The department has consequently described the transaction as suspicious and recommended that it be incorporated into the ongoing investigation.
Suspected Transaction Worth Around Rs 7.20 Lakh
According to the departmental report, assuming a market price of approximately Rs 200 per vial, the suspected transaction involving 3,600 vials would be worth around Rs 7.20 lakh.
Investigators have raised the possibility that medicines may have been purchased, sold or stored using forged or fabricated invoices. The department has also flagged records showing that Kenacort was allegedly sold at prices lower than its purchase cost.
Between May 2025 and March 2026, transactions involving a total of 5,616 vials reportedly showed a loss of around Rs 29,000, which officials have also considered suspicious.
Link to Bharat Pharma Case Under Investigation
The investigation has also established links between the two firms and Bharat Pharma in Aminabad. A case was already registered at Aminabad police station on July 29, 2026, against Bharat Pharma proprietor Devendra Shukla over allegations involving the purchase and sale of counterfeit medicines and their distribution in the market through fraudulent billing.
Drug Inspector Vivek Kumar Singh has now requested that the new facts and evidence emerging during the investigation be incorporated into the existing case. He has also sought an examination of the roles of Bal Govind and Rohit Chadha and appropriate further action under the relevant provisions of the Bharatiya Nyaya Sanhita (BNS).
